
RARE: Rise or Fall? January 16, 2026 Scenario Analysis
RARE January 16, 2026: Critical Resistance Test in Sideways Trend and Breakout Potential
RARE: Rise or Fall? January 15, 2026 Scenario Analysis
1.59BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US90400D1081
CUSIP
90400D108
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-0.24
Book Value
-2.96
Dividend Share
-
Dividend Yield
-
Earnings Share
-5.82
Wall Street Target Price
26.25
EPS Estimate Current Year
-4.08
EPS Estimate Next Year
0.23
EPS Estimate Current Quarter
-0.9971
EPS Estimate Next Quarter
-0.7337
Most Recent Quarter
-
Revenue TTM
717,000,000
Gross Profit TTM
-149,000,000
EBITDA
-465,000,000
Profit Margin
-81.73%
Return On Assets TTM
-24.22%
Return On Equity TTM
-608.47%
Revenue Per Share TTM
7.131
Qtly Revenue Growth YOY
28.10%
Diluted Eps TTM
-5.82
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
2.2413
Price Book MRQ
19.6838
Enterprise Value Revenue
1
Enterprise Value EBITDA
-6
903.08
3.20%227.40
2.97%965.00
0.55%314.92
0.35%900.30
0.00%139.16
0.00%528.21
-4.77%355.10
-2.26%34.64
-2.01%153.70
-1.47%